The company said it will address the observations and respond to the FDA within the stipulated timeframe, reaffirming its ...
BMS is exiting the first U.S.-China pharmaceutical joint venture. Kalexo Bio and Ollin Biosciences have launched with big ...
As the Houston region positions itself to become a national hub for pharmaceutical manufacturing, San Jacinto College is ...
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the best affordable biotech stocks to invest in now. Rigel ...
Learn more about whether Alnylam Pharmaceuticals, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ ...
Innovative Pharmaceutical Biotech ( ($HK:0399) ) just unveiled an announcement. Innovative Pharmaceutical Biotech Limited has announced a further ...
KARACHI: Ali & Associates, in collaboration with the US Consulate General Karachi, successfully hosted a high-level ...
Cash-strapped drug developer LB Pharmaceuticals said on Monday it was aiming for a valuation of up to $321.6 million in its New York initial public offering, potentially setting up the first sizable U ...
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is one of the best affordable biotech stocks to invest in now . Rigel ...
Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition ...
DPA International on MSN
Roche to buy US biotech firm 89bio for up to $3.5 billion
Swiss pharmaceutical giant Roche has agreed to acquire US biotech firm 89bio, a developer of therapies for liver and cardiometabolic diseases, in a transaction valued at up to about $3. 5 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback